Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Trial of Ch14.18 With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma
NCT01041638Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2009
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of dinutuximab in neuroblastoma, sponsored by National Cancer Institute. Started Dec 2009; status: completed.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01041638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01041638.